JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epine...
Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced the successful first-in-human use of ...
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. The Fellowships were presented ...
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...
GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...
Treating diabetes patients earlier with PTG-007 could provide functional cure Recruitment will go ahead after European Medicines Agency approval Comp...
Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP)...
In a groundbreaking alliance announced, the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc. (NASDAQ: RDNT), and the Ame...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced the outcome of a recent successful interaction with the U.S.&nbs...
Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo&r...
© 2026 Biopharma Boardroom. All Rights Reserved.
